More Than a Referral Centre: How the National Aspergillosis Centre Supports Patients and Healthcare Professionals Across the UK

Combining specialist clinical care, diagnostics, multidisciplinary expertise, patient support, education and research to improve outcomes for people living with Chronic Pulmonary Aspergillosis.
The National Aspergillosis Centre (NAC) was established by NHS England to provide highly specialised care for people living with Chronic Pulmonary Aspergillosis (CPA), a serious fungal lung disease that can develop in patients with pre-existing respiratory conditions.
Over the last sixteen years the service has evolved into much more than a referral clinic. Today, NAC combines specialist clinical care, advanced diagnostics, multidisciplinary expertise, patient support, education and research, working alongside local healthcare teams throughout the UK.
Many clinicians are familiar with NAC as a specialist referral service. However, fewer may be aware of the breadth of support available through the centre, including specialist multidisciplinary team discussions, diagnostic expertise, physiotherapy, nursing support, pharmacy services, patient education programmes and nationally recognised fungal diagnostics.
This article provides an overview of how NAC supports both patients and healthcare professionals in the diagnosis and management of Chronic Pulmonary Aspergillosis.
"The National Aspergillosis Centre exists not only to care for patients with Chronic Pulmonary Aspergillosis, but also to support healthcare professionals throughout the UK in diagnosing and managing this complex condition."
Contents
- Why specialist support matters
- What does NAC do?
- Working with local teams
- Benefits for patients
- Benefits for healthcare professionals
- Patient support and education
- Research, education and innovation
- Why awareness still matters
- Further resources
- Working together
Why specialist support matters
Chronic Pulmonary Aspergillosis (CPA) is a serious fungal lung disease that can develop in people with pre-existing respiratory conditions including bronchiectasis, Chronic Obstructive Pulmonary Disease (COPD), previous tuberculosis, sarcoidosis and other structural lung diseases.
Patients may present with chronic cough, breathlessness, fatigue, weight loss, recurrent chest infections or haemoptysis. These symptoms frequently overlap with more common respiratory conditions, making diagnosis challenging.
CPA remains a relatively uncommon disease and many clinicians may encounter only a small number of cases during their careers. As a result, specialist support can be valuable when diagnosis is uncertain, investigations are difficult to interpret or treatment becomes complex.
The National Aspergillosis Centre was established to provide that support.
What does the National Aspergillosis Centre do?
NAC is commissioned by NHS England to provide highly specialised care for patients with Chronic Pulmonary Aspergillosis.
The service supports patients through:
- Specialist assessment and diagnosis
- Multidisciplinary review of complex cases
- Long-term disease monitoring
- Antifungal treatment planning and optimisation
- Therapeutic drug monitoring
- Assessment and management of antifungal resistance
- Management of drug interactions and adverse effects
- Specialist physiotherapy support
- Specialist nursing support
- Access to clinical research and trials
Every new CPA diagnosis is reviewed within a specialist multidisciplinary team, helping to ensure a consistent and evidence-based approach to diagnosis and management.
NAC in 2023–24
- 209 referrals assessed for aspergillosis
- 101 new confirmed CPA diagnoses
- 311 patients under active specialist follow-up
- 71 external cases discussed through the National MDT
- 56 remote advice and guidance consultations
Working with local teams
One of the most common misconceptions about referral is that patients must transfer all of their care to Manchester.
In reality, NAC operates primarily through a shared-care model.
Wherever possible, investigations, imaging, monitoring and routine care are organised locally, with NAC providing specialist input and treatment recommendations. This approach allows patients to benefit from national expertise while remaining close to home.
The service also supports healthcare professionals through remote advice, specialist consultation and participation in the National Multidisciplinary Team (MDT) meeting.
For many clinicians, discussing a case through the MDT can help clarify diagnosis, identify additional investigations and support treatment decisions before or alongside formal referral.
Benefits for patients
Patients referred to NAC gain access to one of the world's largest specialist CPA services.
Benefits include:
- Specialist review by clinicians with extensive experience in fungal lung disease
- Diagnostic clarification and confirmation
- Optimisation of antifungal therapy
- Management of treatment-related complications
- Access to specialist physiotherapy and nursing support
- Educational resources and self-management support
- Opportunities to participate in research
For many patients, specialist review provides reassurance, a clearer understanding of their condition and confidence in their treatment plan.
Benefits for healthcare professionals
The National Aspergillosis Centre exists not only to support patients, but also to support healthcare professionals.
Referral or specialist discussion may be particularly useful when:
- The diagnosis remains uncertain
- Radiological findings are difficult to interpret
- Patients are not responding as expected
- Antifungal toxicity develops
- Resistance is suspected
- A specialist second opinion would be valuable
Clinicians also gain access to expertise in therapeutic drug monitoring, antifungal stewardship, complex fungal diagnostics and long-term disease management.
Each referral creates opportunities for shared learning, helping local teams build experience and confidence in recognising and managing aspergillosis.
Patient support and education
One of the most distinctive features of the National Aspergillosis Centre is the support available beyond routine clinical care.
Many patients referred to NAC have experienced a long and sometimes frustrating journey to diagnosis. Symptoms may have been present for months or years before Chronic Pulmonary Aspergillosis is recognised.
Following diagnosis, patients are often faced with an unfamiliar condition and may encounter alarming information online that relates to very different forms of aspergillosis. It is therefore common for patients and families to feel anxious, isolated and uncertain about what the future may hold.
For this reason, patient support forms an important part of the NAC service.
Through the Community, Awareness, Research, Education and Support (CARES) programme, patients have access to:
- Regular patient support meetings
- Educational webinars and presentations
- Health and wellbeing sessions
- Patient newsletters
- Online information resources
- The Aspergillosis Patients and Carers website
- Peer support opportunities
One of the most common comments from newly diagnosed patients is the relief of discovering that they are not facing the condition alone. Meeting others living with aspergillosis and having access to trusted information can make a significant difference to confidence, understanding and long-term self-management.
"For many patients, finding the CARES programme is the moment they realise they are no longer facing aspergillosis on their own."
By combining specialist clinical care with education, support and community, NAC aims to help patients and families feel informed, supported and empowered throughout their journey.
Research, education and innovation
The National Aspergillosis Centre works closely with the Mycology Reference Centre Manchester (MRCM), one of Europe's leading specialist fungal diagnostic laboratories.
Together, NAC and MRCM contribute to:
- Clinical trials of new antifungal therapies
- Development of new diagnostic techniques
- Antifungal resistance surveillance
- National and international clinical guidelines
- Professional education and training
- Patient-centred research
The partnership has been recognised internationally through European Confederation of Medical Mycology (ECMM) Diamond Centre of Excellence status.
This close integration of clinical care, diagnostics, education and research helps ensure that patients benefit from the latest developments in fungal disease management.
Why awareness still matters
Chronic Pulmonary Aspergillosis remains an under-recognised disease worldwide.
Many patients present with symptoms that overlap with more common respiratory conditions such as COPD, bronchiectasis or previous tuberculosis. As a result, diagnosis can sometimes be delayed or missed.
This is not because clinicians are failing. CPA is an uncommon disease that can closely resemble more familiar respiratory conditions.
The role of NAC is therefore not simply to provide specialist treatment, but also to support earlier recognition of CPA through education, diagnostic support and collaborative working with healthcare professionals throughout the UK.
By raising awareness and improving access to specialist expertise, we hope to help more patients receive timely diagnosis, appropriate treatment and long-term support.
Further resources
- Aspergillosis Patients & Carers Website
- Chronic Pulmonary Aspergillosis Information Hub
- Patient Support Resources
- World Aspergillosis Day Resources
- Mycology Reference Centre Manchester
Working together
The National Aspergillosis Centre was established to ensure that patients with Chronic Pulmonary Aspergillosis have access to specialist expertise wherever they live.
Through shared-care working, multidisciplinary collaboration, specialist diagnostics, patient support, education and research, NAC continues to work alongside healthcare professionals throughout the UK to improve outcomes for people living with fungal lung disease.
Whether through referral, multidisciplinary discussion, specialist advice or educational resources, our aim remains the same: helping clinicians diagnose and manage aspergillosis with confidence while ensuring patients receive the support they need.
NAC is more than a referral centre. It is a national resource for patients, clinicians and healthcare services working together to improve the diagnosis and management of Chronic Pulmonary Aspergillosis.
Why Antifungal Drug Interactions Matter — and How AntifungalInteractions.org Can Help

Key points
- Antifungal medicines used in aspergillosis can interact with many common medicines and supplements.
- Some interactions are mild, while others can significantly affect drug levels or side effects.
- Interactions may involve steroids, inhalers, antibiotics, heart medicines, acid suppressants and herbal supplements.
- Patients should always tell healthcare teams about all medicines, vitamins and supplements they take.
- AntifungalInteractions.org is a specialist resource designed to help healthcare professionals and patients understand potential antifungal interactions.
Why do antifungal interactions matter so much?
The antifungal medicines used to treat aspergillosis are powerful and highly specialised drugs. They are extremely important in controlling fungal disease, but many also affect the way the body processes other medicines.
This is particularly true for azole antifungals such as:
- itraconazole,
- voriconazole,
- posaconazole,
- isavuconazole.
These medicines are processed through enzyme systems in the liver, especially the cytochrome P450 system. Unfortunately, many other medicines also use these same pathways.
This means antifungals can sometimes:
- increase levels of other medicines,
- reduce levels of other medicines,
- increase side effects,
- affect liver function,
- change how well treatments work.
Because aspergillosis patients often take several medicines at the same time, interactions become particularly important.
Common medicines that may interact with antifungals
Not every interaction is dangerous, and many medicines can still be used safely with careful monitoring. However, some combinations require dose adjustments or additional caution.
Steroids and inhalers
Many patients with allergic bronchopulmonary aspergillosis (ABPA), severe asthma or bronchiectasis take steroid medicines.
Interactions can occur with:
- prednisolone,
- methylprednisolone,
- inhaled steroids such as fluticasone or budesonide.
Azole antifungals can increase steroid exposure, potentially increasing the risk of side effects such as:
- weight gain,
- skin thinning,
- high blood sugar,
- adrenal suppression,
- mood changes.
Heart medicines
Some antifungals can affect heart rhythm or interact with medicines used for:
- high blood pressure,
- irregular heartbeat,
- blood thinning,
- cholesterol management.
This is one reason doctors and pharmacists carefully review medication lists before starting antifungal treatment.
Acid suppressants
Medicines used for acid reflux or stomach protection may affect how well some antifungals are absorbed.
This includes:
- omeprazole,
- lansoprazole,
- esomeprazole,
- antacid preparations.
In some cases, antifungal levels may become too low to work effectively.
Antibiotics and other anti-infective medicines
Some antibiotics and antifungals can interact in ways that increase side effects or affect the electrical activity of the heart.
This is particularly important in people already taking multiple medicines.
Supplements and herbal remedies
Patients are often surprised that supplements may also interact with antifungals.
Potential concerns include:
- CBD oil or cannabis products,
- St John’s Wort,
- high-dose vitamins,
- herbal sleep remedies,
- sports supplements.
“Natural” products can still affect liver enzyme systems and may alter medicine levels.
What is AntifungalInteractions.org?
AntifungalInteractions.org is a specialist online interaction checker designed specifically for antifungal medicines.
The site was developed to help healthcare professionals identify and manage potential interactions involving antifungal drugs.
It is widely used internationally and is regularly updated by specialist pharmacy experts.
Why is it useful?
General drug references do not always provide detailed fungal-specific interaction guidance.
AntifungalInteractions.org focuses specifically on antifungal medicines and often provides:
- more detailed interaction information,
- clearer explanations of risks,
- practical management advice,
- colour-coded interaction severity ratings.
This can help patients better understand why clinicians sometimes adjust medicines, order blood tests or recommend monitoring.
Can patients use the website themselves?
Yes — many patients find it useful for understanding their treatment better.
However, it is important not to interpret interaction checkers without context.
An interaction warning does not automatically mean:
- a medicine combination is unsafe,
- treatment must stop,
- harm will definitely occur.
Many interactions can be safely managed by:
- dose adjustments,
- blood test monitoring,
- timing changes,
- careful clinical supervision.
What should patients do?
Patients should try to keep an up-to-date list of:
- prescription medicines,
- inhalers,
- vitamins,
- supplements,
- CBD or cannabis products,
- over-the-counter medicines.
It is particularly important to mention supplements or herbal remedies because these are easily overlooked during clinic visits.
Do not stop medicines without advice
One of the most important messages is that patients should not stop antifungal medicines or other prescribed treatments based only on an online interaction checker.
Antifungal treatment decisions are often carefully balanced against:
- severity of fungal disease,
- lung function,
- other illnesses,
- alternative treatment options.
Healthcare teams can often safely manage interactions once they are aware of them.
The bottom line
Drug interactions are an important part of antifungal treatment, particularly for people living with aspergillosis who may already take several medicines.
AntifungalInteractions.org is an excellent specialist resource that can help patients and healthcare professionals better understand these interactions.
However, online interaction checkers should support discussions with healthcare professionals rather than replace them.
Useful link
Visit AntifungalInteractions.org
BNF to check any other medication interactions
Author and review information
Prepared as general educational information for people affected by aspergillosis and related lung conditions.
This article does not replace personalised medical advice.
Last reviewed: May 2026
When Breathlessness Feels Severe — Even When Oxygen Levels Look “Normal”

Many people living with aspergillosis, severe asthma, bronchiectasis, or other chronic lung conditions describe a confusing and sometimes frightening experience:
“My oxygen saturations are normal, my peak flow is reasonable, there’s little wheeze, but I still feel like I’m drowning.”
This can be distressing for patients and frustrating for carers. Some people feel that because their oxygen levels or breathing tests appear “acceptable”, their symptoms are not fully understood.
Importantly, severe breathlessness can occur even when standard measurements such as oxygen saturations and peak flow readings appear relatively normal.
This does not mean the symptoms are imaginary or “all in the mind”. Breathlessness is complex and can have many different causes.
Why Breathlessness Is More Complicated Than Oxygen Levels
When doctors or nurses assess breathing problems, they often check:
- Oxygen saturation levels (sats)
- Peak flow readings
- Respiratory rate
- Presence of wheeze
- Chest sounds
These are all important. However, they do not always reflect how breathless a person feels.
Some people with chronic respiratory illness may have:
- Normal oxygen saturations
- Reasonable peak flow readings
- Little visible wheeze
- Minimal mucus production
…yet still experience intense sensations of:
- air hunger
- tight chest
- difficulty taking a satisfying breath
- feeling unable to “fill the lungs”
- panic associated with breathing
- extreme fatigue from breathing effort
What Can Cause This?
Breathlessness in aspergillosis and chronic lung disease is often caused by several factors happening together.
Inflammation and Airway Sensitivity
Conditions such as Allergic Bronchopulmonary Aspergillosis (ABPA), Severe Asthma with Fungal Sensitisation (SAFS), bronchiectasis, and Chronic Pulmonary Aspergillosis (CPA) can all cause inflamed and hypersensitive airways.
The lungs may feel irritated or tight even if oxygen exchange remains relatively preserved.
Small Airways Dysfunction
Some breathing problems occur in the smaller airways of the lungs and may not always show clearly on basic tests such as peak flow.
Patients can feel significant chest tightness or air trapping despite “good numbers”.
Muscle Fatigue
Breathing takes muscular effort. Chronic respiratory illness can place a long-term strain on the chest wall and breathing muscles, leading to exhaustion and increased awareness of breathing.
Mucus and Airflow Changes
Even relatively small amounts of mucus or airway narrowing can create sensations of chest heaviness or difficulty moving air.
Breathing Pattern Dysfunction (Dysfunctional Breathing)
This is increasingly recognised in people with chronic respiratory illness.
When breathing becomes difficult over months or years, people may unconsciously develop altered breathing patterns, including:
- rapid shallow breathing
- upper chest breathing
- frequent sighing
- over-breathing (hyperventilation)
- muscle tension around the chest and neck
This can worsen symptoms and create a vicious cycle where the sensation of breathlessness becomes amplified.
Symptoms may include:
- air hunger
- dizziness
- tingling
- tight chest
- panic sensations
- difficulty “switching off” breathing awareness
Importantly, this does not mean the illness is psychological or “not real”. Dysfunctional breathing can happen alongside genuine lung disease.
Why Inhalers Sometimes Seem to Help Less
Reliever inhalers such as salbutamol (Ventolin) are designed mainly to relax tightened airways.
If breathlessness is being driven partly by breathing pattern dysfunction, muscle fatigue, inflammation, hypersensitivity, or air trapping, inhalers may not always provide dramatic relief.
This can be confusing and upsetting for patients.
“But My Tests Are Normal…”
Many patients feel frustrated, frightened, or even dismissed when told that oxygen levels, peak flow readings, or chest examinations are “fine” despite severe breathlessness.
Normal oxygen saturations are reassuring in terms of immediate danger, but they do not always reflect the full experience of chronic respiratory illness.
Breathlessness is influenced by many factors including inflammation, airway sensitivity, breathing effort, muscle fatigue, anxiety associated with struggling to breathe, and altered breathing patterns.
Because of this, some people may feel profoundly breathless even when routine measurements appear relatively stable.
It can sometimes help to explain symptoms in practical, functional terms, such as:
- “I become breathless walking across the room.”
- “I recover much more slowly than usual.”
- “This feels much worse than my normal baseline.”
- “I feel exhausted by the effort of breathing.”
- “Breathing exercises seem to help settle things.”
These descriptions may help healthcare professionals understand how symptoms are affecting day-to-day life, rather than focusing only on oxygen levels or peak flow numbers.
Some patients also find it helpful to ask questions such as:
- Could breathing pattern dysfunction be contributing?
- Would respiratory physiotherapy help?
- Would pulmonary rehabilitation be appropriate?
- How should I judge when symptoms need urgent assessment?
Importantly, severe breathlessness should never simply be ignored. New, worsening, or unusual symptoms still require proper medical assessment.
At the same time, many people with chronic lung disease experience very real symptoms that are not always fully reflected by routine measurements alone.
Why Breathlessness Can Feel So Frightening
The sensation of breathlessness is created by the brain interpreting signals from the lungs, breathing muscles, chest wall, blood chemistry, and nervous system.
This means that the feeling of “not getting enough air” is not determined only by oxygen levels.
In chronic lung disease, several things can trigger the sensation of breathlessness, including:
- inflamed or sensitive airways
- extra effort needed to move air in and out
- air trapping in the lungs
- muscle fatigue
- rapid or shallow breathing
- stress hormones released during breathing distress
- heightened awareness of breathing sensations
When breathing becomes uncomfortable, the body naturally responds with anxiety and adrenaline. This is a protective survival response.
Unfortunately, this can sometimes create a cycle:
breathlessness → anxiety → faster breathing → more chest tightness → worse breathlessness
This does not mean symptoms are “psychological”. The physical sensation is real, but the body’s alarm systems can unintentionally amplify it.
What Can Help During an Episode of Breathlessness?
Different techniques help different people, and severe or rapidly worsening symptoms should always be medically assessed. However, some patients find the following approaches helpful during episodes of distressing breathlessness:
Slow the Breathing Rate
Trying to slow breathing gently can help reduce over-breathing and chest tightness.
Some people find it helpful to:
- breathe in gently through the nose
- breathe out slowly through pursed lips
- focus on making the out-breath longer than the in-breath
Use a Recovery Position
Sitting forward slightly with the arms supported on knees or a table can sometimes reduce the work of breathing.
Reduce Panic and “Air Hunger”
Trying to fight for bigger and bigger breaths can sometimes worsen symptoms.
Some patients find it more helpful to focus on:
- gentle breathing rhythm
- relaxing the shoulders and neck
- slowing breathing rather than deepening it
- focusing attention away from the chest where possible
Use Prescribed Treatments Appropriately
Follow the advice provided by your healthcare team regarding inhalers, nebulisers, airway clearance, or rescue medication.
If inhalers are not helping as expected, this should be discussed with a respiratory specialist rather than simply increasing use repeatedly.
Know Your “Usual” Pattern
Many patients find it useful to learn the difference between:
- their “usual” chronic breathlessness
- breathing pattern dysfunction or over-breathing episodes
- symptoms suggesting infection or acute deterioration
This can help patients feel more confident recognising when urgent medical assessment may be needed.
Can Breathing Retraining Help?
Some patients find breathing retraining exercises very helpful, especially when guided by:
- respiratory physiotherapists
- specialist breathing services
- pulmonary rehabilitation teams
- asthma nurse specialists
Breathing retraining may include:
- slowing breathing rate
- diaphragmatic (“belly”) breathing
- nasal breathing techniques
- recovery breathing positions
- relaxation techniques
- paced activity and pacing strategies
Some NHS respiratory teams recommend online breathing resources and guided exercises to help patients recognise and manage over-breathing patterns.
These approaches are usually intended to work alongside medical treatment — not instead of it.
Living With an “Invisible” Symptom
One of the hardest aspects of chronic breathlessness is that outward signs may not always match how severe symptoms feel internally.
Many patients report feeling dismissed when oxygen levels are normal or when tests appear “better than expected”.
The experience of breathlessness is real, even when routine measurements do not fully explain it.
This is one reason why specialist respiratory assessment can be important in complex conditions such as aspergillosis.
When to Seek Medical Help
You should seek urgent medical advice if breathlessness is:
- suddenly worsening
- associated with chest pain
- causing blue lips or fingertips
- associated with falling oxygen saturations
- accompanied by fever or signs of infection
- causing confusion or severe exhaustion
- significantly different from your usual symptoms
Even if previous episodes have been related to breathing pattern dysfunction, new or worsening symptoms should still be medically assessed.
Further Support
You may also find these resources helpful:
Last reviewed: May 2026
Produced by: National Aspergillosis Centre CARES Team / Aspergillosis Website
Can Aspergillosis Be Cured? Understanding Treatment, Control, and Long-Term Therapy
Last reviewed: April 2026
Key points
- Aspergillosis is caused by fungi from the Aspergillus group.
- Most people breathe in Aspergillus spores regularly without becoming ill.
- In some people, damaged airways, lung cavities, mucus plugs, or immune responses allow the fungus or fungal material to persist.
- Antifungal treatment may aim to cure, but in many cases the goal is long-term control.
- Steroids can reduce harmful inflammation in allergic disease, but they can also reduce the body’s ability to clear fungus.
Table of contents
- Overview
- Why breathing in spores does not usually cause disease
- Why aspergillosis can be hard to clear
- Infection and ABPA: different reasons for persistence
- Do steroids influence this?
- Control vs cure
- Common antifungal treatments
- Why you may not hear many success stories
- When to seek medical advice
- Common questions
Overview
It is very common for people diagnosed with aspergillosis to feel worried when they read that others have been taking antifungal medication for months or even years.
This can lead to an understandable question:
“Does treatment actually work, or will I have this forever?”
The answer is more nuanced than a simple yes or no. Different forms of aspergillosis behave differently, and treatment goals vary depending on the condition.
Two of the most common conditions are:
- Allergic Bronchopulmonary Aspergillosis (ABPA) – an allergic immune reaction to Aspergillus in the airways
- Chronic Pulmonary Aspergillosis (CPA) – a long-term fungal infection, usually in areas of damaged lung tissue
Understanding this difference is key to understanding why treatment may continue for a long time.
If you would like a more detailed explanation of how these conditions are diagnosed and managed, see our guides to chronic pulmonary aspergillosis (CPA) and allergic bronchopulmonary aspergillosis (ABPA).
Why breathing in spores does not usually cause disease
Aspergillus spores are present in the environment, including air, soil, compost, dust, and decaying vegetation. Most people breathe in small numbers of these spores regularly without becoming ill.
In healthy lungs, spores are usually cleared by the immune system and by the normal cleaning mechanisms of the airways.
This means:
- Exposure to Aspergillus is common
- Most exposure does not lead to disease
- Aspergillosis usually develops only when there are additional risk factors, such as lung damage, mucus trapping, or altered immune responses
So it is not accurate to think of most patients as being “constantly reinfected”. A better way to think about it is that some lungs provide conditions where Aspergillus, or fungal material, can persist and continue to cause problems.
Why aspergillosis can be hard to clear
Aspergillosis can be difficult to clear for several reasons. These include the structure of the lungs, the biology of the fungus, limitations of drug penetration, and the way the immune system responds.
1. Damaged lung tissue can provide protected spaces
In CPA, Aspergillus often grows in areas of abnormal lung, such as cavities, scarred tissue, or areas affected by bronchiectasis.
These areas can act as protected spaces where the fungus is harder for the immune system and antifungal medicines to reach.
2. Thick mucus can trap fungus and fungal material
In airway diseases such as asthma, bronchiectasis, and ABPA, thick mucus can trap spores, hyphae, and fungal fragments.
This trapped material can continue to stimulate inflammation even when the fungus is not invading lung tissue.
3. Antifungal medicines may suppress rather than sterilise
Antifungal medications can reduce fungal activity and help prevent progression, but they may not always remove every trace of fungus from damaged lung spaces or mucus-filled airways.
For this reason, success is often measured by:
- Improved symptoms
- Stabilised weight and energy
- Fewer flare-ups
- Stable or improved scans
- Prevention of further lung damage
Infection and ABPA: different reasons for persistence
Chronic pulmonary aspergillosis: persistence of infection
In chronic pulmonary aspergillosis, the problem is fungal growth in damaged lung tissue.
- Lung cavities provide spaces where fungus can grow
- Drug penetration may be limited
- The immune system may not fully clear infection
Allergic bronchopulmonary aspergillosis: persistence of reaction
In ABPA, the main issue is an exaggerated immune response.
- Mucus traps fungal material
- Small amounts can trigger strong reactions
- Inflammation leads to more mucus
Do steroids influence this?
Yes. Steroids can be helpful but must be used carefully.
In ABPA, they reduce inflammation but may also reduce fungal clearance.
In chronic infection, steroids can increase the risk of persistence or progression.
Monitoring and drug interactions are important during treatment.
Control vs cure: what is the goal?
For many people, the realistic goal is:
- Stability rather than eradication
- Reduced symptoms
- Prevention of progression

Common antifungal treatments
- Itraconazole
- Voriconazole
- Posaconazole
These treatments are selected based on individual factors and require monitoring.
Why don’t I hear many success stories?
People who improve often post less, while those still struggling are more visible in forums.
When to seek medical advice
- Uncertainty about treatment
- Side effects
- Weight loss
- Worsening symptoms
Common questions
Can aspergillosis be cured?
Sometimes, but often it is managed long-term.
Are people constantly reinfected?
No. Most people clear spores regularly without issue.
Why is ABPA difficult to treat?
Because of ongoing immune reactions and mucus trapping.
Further reading
- Chronic Pulmonary Aspergillosis (CPA)
- Allergic Bronchopulmonary Aspergillosis (ABPA)
- Antifungal medicines
When ‘chest infections’ don’t respond: when to suspect ABPA or CPA (Clinical perspective)
Patients presenting with recurrent “chest infections” that do not respond to antibiotics are common in primary and secondary care. In a subset of these cases, the underlying cause may not be bacterial, but related to fungal disease or immune-mediated responses to Aspergillus.
This article summarises when to suspect allergic bronchopulmonary aspergillosis (ABPA) or chronic pulmonary aspergillosis (CPA), and how to move from repeated empirical treatment to a more structured diagnostic approach.
Key clinical message
Repeated antibiotic-treated exacerbations with limited response, particularly when symptoms improve with steroids and then relapse, should prompt reconsideration of the diagnosis.
When to suspect ABPA or CPA
Consider aspergillosis-related disease in patients with:
- Recurrent “chest infections” with poor or inconsistent antibiotic response
- Steroid-responsive symptoms with relapse on reduction or cessation
- Persistent or unexplained radiological abnormalities
- Underlying lung disease:
- Asthma
- Bronchiectasis
- Chronic obstructive pulmonary disease (COPD)
- Previous tuberculosis or lung damage
- Raised or previously documented abnormalities in:
- Total IgE
- Eosinophils
- Aspergillus-specific markers (if previously tested)
These features are not diagnostic in isolation but should raise suspicion when seen together.
ABPA vs CPA: clinical distinction
| Feature | ABPA | CPA |
|---|---|---|
| Primary mechanism | Immune-mediated (allergic) | Chronic fungal infection |
| Typical background | Asthma, bronchiectasis | Structural lung disease, prior TB, COPD |
| Steroid response | Often marked | Variable (may improve symptoms but not disease) |
| Antibiotic response | Limited | Limited |
| Radiology | Mucus plugging, bronchiectasis | Cavities, fungal balls, fibrosis |
Common pitfalls in practice
- Repeated empirical antibiotics despite poor response
- Short courses of steroids without a long-term management plan
- Reliance on chest X-ray alone in persistent or atypical cases
- Failure to recognise patterns across multiple consultations or admissions
These patterns can lead to prolonged diagnostic delay, which is well described in CPA and ABPA.
Suggested diagnostic approach
1. Reassess the working diagnosis
When standard treatment fails, explicitly reconsider whether the presentation remains consistent with bacterial infection.
2. Imaging
- Escalate from chest X-ray to CT thorax where appropriate
- Look for:
- Cavitation
- Fungal ball (aspergilloma)
- Mucus plugging
- Bronchiectasis
3. Blood tests
- Total IgE
- Eosinophil count
- Aspergillus-specific IgE and IgG (where available)
4. Microbiology / further testing
Depending on context, consider sputum culture, fungal markers, or specialist input.
The steroid–relapse pattern
A common clinical scenario:
Exacerbation → steroids → improvement → relapse
This should raise suspicion of an underlying inflammatory or fungal-driven process rather than recurrent bacterial infection alone.
When to consider referral
Referral to a specialist centre (e.g. National Aspergillosis Centre, Manchester) may be appropriate where:
- Diagnosis remains uncertain
- Symptoms are persistent or progressive despite treatment
- Antifungal therapy is being considered or not tolerated
- Radiology suggests CPA or complex disease
Referral decisions should be made in the context of overall patient condition, comorbidities, and goals of care.
Why diagnosis is often delayed
- Overlap with common respiratory conditions
- Partial response to standard therapies
- Fragmentation across care settings
- Limited exposure to aspergillosis in routine practice
Recognising the pattern is often the key step in reducing delay.
Practical takeaways
- If antibiotics are not working, reconsider the diagnosis
- If steroids repeatedly improve symptoms, ask why
- Use CT imaging to clarify persistent abnormalities
- Aim for a clear, shared management plan
Guidelines and further reading
- British Thoracic Society. Clinical Statement on Aspergillus-related chronic lung disease
- ISHAM Working Group. Guidelines for ABPA diagnosis and management
- Denning DW et al. Chronic pulmonary aspergillosis guidelines
Further professional resources
Aspergillosis.org – Information for healthcare professionals
This article is intended for educational purposes and should be interpreted in the context of individual clinical judgement.
Can overseas patients access specialist centres like NAC? A clear guide for patients and families
Last reviewed: April 2026
Key points
- Specialist centres such as the National Aspergillosis Centre (NAC) cannot provide individual medical advice directly to patients, especially from overseas.
- This is due to safety, legal, and clinical responsibility requirements.
- The correct route is through a local doctor, using a formal referral process.
- A referral does not guarantee that a patient will be seen.
- Even when doctors contact specialist centres, there are limits to what can be offered.
- NAC does not offer private care, although some other centres do.
Table of contents
- Why can’t specialist centres respond directly?
- The correct way to get help
- What does a referral mean?
- Will a referral always be accepted?
- Do personal requests help?
- Limits even when doctors are involved
- What about private care?
- Common myths
- When to seek urgent help
Why can’t specialist centres respond directly to patients?
It is natural to want to contact a specialist centre directly, especially when dealing with a complex condition such as aspergillosis. However, centres like NAC cannot provide individual medical advice directly to patients.
This is not a matter of choice—it is because they cannot safely or legally do so.
Patient safety
- Safe medical advice requires full access to medical records, test results, and examination findings
- Doctors must be able to monitor progress and adjust treatment
- This cannot be done through messages or emails alone
Legal and regulatory requirements
- Doctors must follow strict rules set by regulators such as the General Medical Council (GMC) in the UK
- They cannot take responsibility for a patient without a formal clinical relationship
Responsibility for care
- Any doctor giving advice must be able to take responsibility for outcomes
- This requires recognised clinical pathways and follow-up arrangements
In summary: Specialist centres are not refusing help—they cannot provide care outside safe and regulated systems.
The correct way to get help
The safest and most effective way to access specialist expertise is through your local doctor.
Step 1 – See a local specialist
- Respiratory doctor
- Infectious disease specialist
- Internal medicine specialist
Step 2 – Assessment and initial care
- Your doctor reviews your symptoms and history
- Tests are arranged where needed
- Treatment may be started
Step 3 – Referral or specialist advice
- Your doctor may refer you to a specialist centre
- Or they may contact a centre such as NAC for advice
This approach ensures your care is coordinated, safe, and based on full clinical information.
What does a referral mean?
A referral is when your doctor formally asks another specialist or centre to review your case or consider seeing you.
This is not just a message—it is a structured clinical process.
What does a referral usually include?
- Your medical history
- Details of your symptoms
- Results of tests (such as scans or laboratory results)
- Treatments you have already received
- A clear reason for referral
This allows the specialist centre to understand your situation safely and properly.
What happens next?
After reviewing the referral, the specialist centre may:
- ✔️ Accept the referral and arrange an appointment
- ✔️ Provide advice to your doctor without seeing you
- ✔️ Suggest a more appropriate service
- ❌ Decline the referral
A referral is like a formal handover between doctors—it does not guarantee an appointment.
Will a referral always be accepted?
Even when your doctor makes a referral, it is important to understand that the referral may not always be accepted.
Why might a referral not be accepted?
Eligibility criteria
- Specialist centres often have strict criteria for the patients they can see
- Some services are commissioned only for specific conditions
Geographic and funding rules
- Access may depend on healthcare system or funding arrangements
Clinical suitability
- The centre may decide your care can be managed locally
- They may offer advice instead of accepting the referral
Capacity
- Specialist centres often manage large numbers of complex patients
What happens if it is not accepted?
- Your doctor may still receive expert advice
- You may be directed to another service
- Your care continues locally
This does not mean you are being refused help.
Why specialist centres may not be able to confirm anything to you
Patients and families sometimes ask a specialist centre whether a referral has been received, reviewed, or accepted.
It is important to understand that the centre may not be able to confirm or discuss this with you directly.
Why is this?
Confidentiality and data protection
- Medical information is protected by strict confidentiality rules
- In the UK, this includes laws such as data protection legislation and professional duties of confidentiality
- Centres must be certain they are communicating with the correct person and through approved channels
Communication is usually between doctors
- Referrals are handled as clinician-to-clinician communication
- Responses are normally sent back to the referring doctor, not directly to the patient
No confirmation does not mean no action
- If you do not receive a reply from the centre, it does not necessarily mean your referral has been ignored
- Advice or decisions may already have been communicated to your doctor
What should you do?
- Contact your own doctor for updates
- Ask whether a referral has been sent and if a response has been received
- Discuss next steps with your clinical team
Summary
Specialist centres usually communicate with your doctor, not directly with patients. This is to protect your privacy and ensure safe, appropriate communication.
Do personal requests from patients or families help?
Personal requests are completely understandable, but specialist centres cannot provide individual medical advice directly to patients, even in urgent situations.
This is because they cannot safely or legally do so without a doctor involved.
These requests may still help with general information and guidance, but they do not usually lead to diagnosis or treatment advice.
Limits even when doctors are involved
When your doctor contacts a specialist centre, this is the correct route—but there are still limits.
What specialist centres can offer
- Expert opinion
- Suggestions for diagnosis
- Guidance on tests
- Interpretation of results
What they cannot usually provide
- Direct patient care
- Full responsibility for treatment
- Definitive diagnosis without full assessment
Your local doctor remains responsible for your care.
What about private care?
The National Aspergillosis Centre (NAC) does not offer private care.
- You cannot arrange to be seen there privately
- Access is through NHS referral pathways only
Some other specialist centres may offer private consultations. However:
- A referral and medical records are usually required
- An in-person assessment is typically needed
- Private care does not bypass safety or legal requirements
Common myths
- “I can contact a specialist centre directly for help”
→ Centres cannot provide individual advice directly to patients - “If it’s urgent, they will make an exception”
→ The same safety rules apply to all patients - “A referral guarantees I will be seen”
→ Referrals are reviewed and may not always be accepted - “Private care means I can be seen anywhere”
→ Not all centres offer private care (NAC does not) - “A detailed email is enough for diagnosis”
→ Diagnosis requires full clinical assessment
When to seek urgent medical help
If you or someone you care for has any of the following, seek urgent local medical care:
- Severe breathlessness
- Chest pain
- Coughing up blood
- Confusion or extreme drowsiness
- High fever that is not improving
Do not delay seeking help while trying to contact overseas specialists.
Summary
Specialist centres such as NAC play an important role in supporting complex conditions like aspergillosis. However, they must work within systems designed to keep patients safe.
The most effective way to access their expertise is through your own doctor, using formal referral pathways and specialist advice where needed.
Author & review information
Prepared for patient education purposes.
Aligned with UK specialist centre practice and patient safety guidance.
References & further reading
- General Medical Council (UK) – Good medical practice
- NHS England – Specialist services referral guidance
- European Lung Foundation – Aspergillosis information
- National Aspergillosis Centre – aspergillosis.org
AntifungalInteractions.org – A Specialist Resource for Safer Antifungal Treatment
Last reviewed: April 2026
Managing antifungal medications can be complex. Many antifungal drugs interact with other medicines, foods, and even supplements.
To support both patients and healthcare professionals, a dedicated resource is available:
AntifungalInteractions.org.
Key Points
- A specialist database focused specifically on antifungal drug interactions
- More detailed and targeted than general resources such as the British National Formulary (BNF)
- Includes guidance designed for both healthcare professionals and patients
- Regularly updated (typically several times per month)
- Maintained by an experienced clinical pharmacist and prescriber
- Owned and supported by the Fungal Infection Trust
What is AntifungalInteractions.org?
AntifungalInteractions.org is a dedicated online database designed to help users understand how antifungal medications interact with:
- Other prescribed drugs
- Over-the-counter medications
- Herbal supplements
- Certain foods and drinks
Unlike general drug reference tools, this resource focuses specifically on antifungal medicines, making it particularly useful for conditions such as aspergillosis, where treatment often involves long-term or complex therapy.
Why This Resource Matters
1. Antifungal drugs are complex
Common antifungal medications such as azoles (e.g. itraconazole, voriconazole, posaconazole) are known to interact with many other drugs.
These interactions can:
- Increase side effects
- Reduce treatment effectiveness
- Require dose adjustments or monitoring
2. General resources may not go far enough
Widely used tools like the British National Formulary (BNF) are essential, but they are designed for broad use across all medicines.
AntifungalInteractions.org provides:
- More detailed interaction explanations
- Practical interpretation of risk
- Condition-specific relevance
3. It supports informed discussions
The database is not a replacement for clinical advice, but it can help patients and clinicians:
- Prepare for consultations
- Understand potential risks
- Ask more informed questions
Who Maintains the Database?
AntifungalInteractions.org is maintained by:
Saarah Niazi-Ali
MPharm, PG Cert (General Pharmacy Practice), PG Dip (Advanced Clinical Pharmacy Practice),
Independent Pharmacist Prescriber, Non-Medical Prescribing (Level 7), Final Medical Signatory
The database is updated frequently—typically 3–4 times per month, often on a weekly basis—ensuring that information remains current and clinically relevant.
Governance and Ownership
The resource is owned and supported by the Fungal Infection Trust, a UK-based organisation dedicated to improving the understanding, diagnosis, and treatment of fungal diseases.
This ensures that the database:
- Remains focused on patient benefit
- Is aligned with specialist fungal disease care
- Supports both clinical practice and patient education
Who Is It For?
Patients and carers
- To better understand their medications
- To check for potential interactions
- To support conversations with their clinical team
Healthcare professionals
- Infectious disease specialists
- Respiratory clinicians
- Pharmacists
- GPs managing complex patients
It is particularly valuable for clinicians managing conditions such as:
- Chronic pulmonary aspergillosis (CPA)
- Allergic bronchopulmonary aspergillosis (ABPA)
- Other fungal infections requiring long-term antifungal therapy
How Does It Compare to Other Resources?
| Feature | AntifungalInteractions.org | General Drug References (e.g. BNF) |
|---|---|---|
| Focus | Antifungal-specific | All medicines |
| Level of detail | High (specialist) | Moderate (broad coverage) |
| Patient-friendly explanations | Yes | Limited |
| Update frequency | Frequent (monthly/weekly) | Regular but broader scope |
Important Notes for Patients
While this database is a valuable resource, it should be used appropriately:
- Do not stop or change medication based on what you read
- Always discuss concerns with your doctor, pharmacist, or specialist team
- Use the information to support—not replace—medical advice
When to Seek Medical Advice
Contact your healthcare provider if you:
- Start a new medication while on antifungal treatment
- Experience new or worsening side effects
- Are unsure whether a supplement or food is safe
- Have been advised of a potential interaction
Summary
AntifungalInteractions.org is a highly valuable, specialist resource that fills an important gap in antifungal care.
Its combination of:
- Expert clinical oversight
- Frequent updates
- Patient-accessible explanations
- Specialist focus
makes it an important tool for both patients and healthcare professionals managing fungal disease.
Further Reading
- British National Formulary (BNF)
- Aspergillosis treatment guidance (aspergillosis.org)
Author & Review
Prepared for Aspergillosis patient and healthcare education.
Content aligned with UK specialist practice and reviewed for clarity and safety.
Aspergillosis and Diet: coping with weight loss, poor appetite, food avoidance and stomach symptoms
For: patients, carers, general practitioners, specialist nurses and other non-specialists
Last reviewed: 8 April 2026
Important: This page is general information. It does not replace advice from your own clinical team.
Key points
- Eating difficulties are common in aspergillosis, especially in chronic pulmonary aspergillosis (CPA) and in people who also have other lung disease.
- The problem is often not simply “poor appetite”. Breathlessness, cough, fatigue, reflux, nausea, altered taste and medicine side effects can all make eating difficult.
- Some people gradually cut out more and more foods because eating feels uncomfortable or because they have been told certain foods are “bad” for lung symptoms.
- For many patients, the main nutritional goal is not a “perfect” diet. It is getting enough energy, protein and fluids in ways that feel manageable.
- “Little and often”, food fortification and nourishing drinks are often more realistic than trying to eat three large meals a day.
- Ongoing weight loss, a very restricted diet, persistent nausea, reflux or difficulty eating most days should be discussed with a doctor, specialist team or dietitian.
Why diet can become a major problem in aspergillosis
Many people living with aspergillosis find that eating becomes much harder than it used to be. This is particularly important in chronic pulmonary aspergillosis (CPA), where weight loss, fatigue and general ill health are common features of the illness. In practical terms, the body may need more energy while the person is less able to eat comfortably.
Several problems can overlap:
- Breathing takes more effort, which can increase energy needs.
- Coughing or breathlessness can interrupt meals.
- Tiredness can make shopping, cooking and eating feel like hard work.
- Inflammation and chronic illness can reduce appetite and contribute to muscle loss.
- Antifungal treatment and other medicines can cause nausea, altered taste, indigestion or poor appetite.
- Reflux, bloating or early fullness may mean that even small meals feel uncomfortable.
For some patients this creates a vicious circle: eating becomes unpleasant, intake falls, weight drops, strength falls, and eating may then feel even more difficult.
Who is most affected?
Not every patient with aspergillosis has major nutritional problems, but some groups are more likely to struggle. This includes people with:
- Chronic pulmonary aspergillosis (CPA)
- pre-existing lung disease such as chronic obstructive pulmonary disease (COPD), bronchiectasis or previous tuberculosis
- long-term fatigue, breathlessness or coughing
- persistent nausea or reflux symptoms
- a history of recent unplanned weight loss
- side effects from antifungal or other medicines
- anxiety around eating because meals repeatedly trigger symptoms
Some people with allergic bronchopulmonary aspergillosis (ABPA) also report poor intake or nutritional difficulties, although the pattern may differ from CPA. In ABPA, steroid treatment, asthma burden, medicine effects and general symptom load may all influence diet.
How eating can become difficult
People often describe eating problems in ways that do not sound like a classic “nutrition” issue. They may say things like:
- “I get full after a few mouthfuls.”
- “I cannot face a proper meal.”
- “Eating makes me cough.”
- “I feel uncomfortable after food.”
- “Some foods seem to sit badly.”
- “I only eat a few safe foods now.”
These experiences are important. They suggest that the real problem may be a mixture of breathlessness, upper gastrointestinal symptoms, medicine effects and learned food avoidance, not simply a lack of willpower or poor food choices.
When eating shrinks into a “minimal diet”
Some patients end up eating very little, often because that feels safer or more manageable than trying to eat normally. A “minimal diet” may look like:
- very small amounts of food only once or twice a day
- mostly soft or liquid foods
- reliance on tea, toast, soup or yoghurt
- long gaps without eating
- skipping meals because eating feels exhausting
This is understandable, but it can become a serious problem. Small intake over time may lead to:
- weight loss
- loss of muscle mass
- greater weakness and fatigue
- slower recovery from illness
- reduced ability to cope with infections or treatment
If a patient is managing only tiny amounts of food, the first goal is often not to rebuild a “normal” diet immediately. It is to make intake easier, more comfortable and more nourishing.
Avoiding many food types
Another common pattern is gradual food restriction. Patients may stop eating several food groups because they believe these foods worsen mucus, cough, reflux, nausea or fungal disease.
Examples include avoiding:
- dairy products
- sweet foods
- bread or dry foods
- meat
- acidic foods
- foods linked in the mind to a previous bad episode
Sometimes there is a genuine reason for avoiding a particular food. For example, reflux may make acidic or very fatty foods uncomfortable, and a dry crumbly food may clearly trigger coughing. The difficulty is that repeated bad experiences can also lead to over-restriction, where more and more foods are cut out than is really necessary.
That can leave the diet low in calories, low in protein and very repetitive. In practice, the aim is usually to adapt foods rather than cut out whole food groups unless there is a clear reason to avoid them.
Could the stomach or gut be part of the problem?
Yes. This is often overlooked.
Some patients with aspergillosis describe symptoms that sound mainly digestive rather than respiratory, for example:
- nausea
- heartburn or reflux
- bloating
- feeling full very quickly
- upper abdominal discomfort
- reduced appetite after starting or changing medication
- alternating diarrhoea and constipation
There are several possible reasons:
- Medicine side effects, including antifungals
- Gastro-oesophageal reflux disease (GORD), which can also worsen cough
- reduced activity levels and chronic illness
- constipation, especially when intake is poor or medicines contribute
- co-existing gastrointestinal disease that is separate from aspergillosis
If eating repeatedly causes upper abdominal or chest discomfort, or if reflux and nausea are prominent, it is reasonable to think of this as a symptom needing review rather than simply a “fussy eating” problem.
Practical ways to make eating easier
Different things help different people, but these approaches are often more realistic than trying to push through large meals.
1. Think “little and often”
Many people do better with five or six small eating opportunities through the day instead of three big meals. That may mean a small breakfast, a mid-morning snack, a light lunch, a nourishing drink, an evening meal and a supper snack.
2. Lower the effort of eating
Soft, moist foods are often easier than dry, chewy or crumbly foods. Examples include:
- porridge
- yoghurt
- custard or rice pudding
- mashed potato with added butter or cheese
- scrambled eggs
- soup with cream or grated cheese
- stews, casseroles or sauced dishes
3. Use drinks as nutrition
For some patients, drinks are easier to manage than food. Nourishing options can include:
- milky drinks
- smoothies
- milkshakes
- fortified hot drinks
- commercial oral nutritional supplements if prescribed or advised
4. Rest before eating
If fatigue or breathlessness are major barriers, it can help to eat after a rest rather than after exertion. Some people find breakfast or lunch easier than an evening meal.
5. Sit upright and stay upright afterwards
This can be especially helpful when reflux, coughing or chest discomfort are part of the picture.
6. Slow the pace
It is acceptable to eat slowly and pause often. Some patients benefit from smaller mouthfuls and short breathing pauses between them.
7. Look for manageable variety
If the diet has become very narrow, widening it gently may be more successful than trying to overhaul everything at once.
How to support weight maintenance
When keeping weight on is difficult, the most useful approach is often to increase the energy and protein content of what is already being tolerated.
Food-first ideas
- Add butter, cream, cheese, yoghurt, milk powder or olive oil to foods where suitable.
- Choose full-fat products rather than “diet” versions if weight loss is a concern.
- Add grated cheese to soup, mashed potato, scrambled eggs or vegetables.
- Make porridge with milk rather than water.
- Keep easy snacks available, such as yoghurts, cheese and crackers, peanut butter, hummus, custard, rice pudding or milky desserts.
Protein matters
Protein helps preserve muscle. Good sources include:
- milk, yoghurt and cheese
- eggs
- meat, fish and poultry if tolerated
- beans, lentils and other pulses
- nut butters where suitable
Oral nutritional supplements
When food alone is not enough, a doctor or dietitian may suggest oral nutritional supplements. These are often used between meals rather than instead of meals. They can be particularly helpful when appetite is low or meal size is very limited.
In general UK nutrition practice, a “food first” approach is usually tried first where appropriate, but oral nutritional supplements are commonly used when someone is at higher risk of malnutrition or is unable to meet needs from food alone.
Food and medicine issues to remember
Food and medicine can interact in two main ways.
1. Medicines can affect eating
Antifungal treatment and other medicines may contribute to:
- nausea
- indigestion
- altered taste
- poor appetite
- bowel upset
If these symptoms started after a medicine was introduced or changed, it is worth discussing that with the prescribing team.
2. Food can affect medicines
Some antifungal medicines have specific instructions about when to take them in relation to food. For example:
- Itraconazole capsules are generally taken with or just after food, while itraconazole liquid is generally taken on an empty stomach.
- Voriconazole is usually taken on an empty stomach.
- Some medicines also have important interactions with antacids or acid-suppressing medicines.
Because formulations differ, and because other medicines may also interact, patients should follow the instructions they have been given for their exact preparation and check with a pharmacist or clinical team if unsure.
Grapefruit and other food interactions: some medicines have clinically important food interactions. Patients should check current advice for each medicine rather than relying on memory or online generalisations.
Common diet myths
Dairy always makes mucus worse
This is a very common belief. Current evidence does not show that dairy routinely increases lung mucus production for most people. Some people do notice a thicker mouth or throat feeling after milk, which may relate to texture rather than extra mucus. If dairy is well tolerated, it can be a useful source of calories and protein.
Sugar “feeds” aspergillosis, so it should be cut out completely
Patients often hear this online, but strict self-imposed restriction can be more harmful than helpful when someone is already struggling to maintain intake. For many patients with weight loss, the immediate nutritional priority is adequate calories and protein, not aggressive dietary exclusion.
There is a special anti-aspergillosis diet
There is no widely accepted specialist diet that treats aspergillosis itself. In routine practice, nutrition advice usually focuses on preventing or treating malnutrition, easing symptoms and managing medicine-related issues.
If eating is difficult, I should just avoid more foods
Sometimes a food really is hard to tolerate, but repeated restriction can shrink the diet too far. Often it is more useful to ask, “Can this be made easier to eat?” rather than “Should I cut this out altogether?”
When to seek medical help
Patients should speak to their doctor, specialist team or another qualified healthcare professional if they have any of the following:
- ongoing unplanned weight loss
- clothes, rings or dentures becoming looser
- difficulty eating most days
- a very narrow diet with only a few “safe” foods
- persistent nausea, reflux, bloating or abdominal discomfort
- increasing weakness or fatigue
- concerns that medicines are worsening appetite or stomach symptoms
It may be appropriate to ask about a dietitian referral, especially if intake has been poor for some time or there are signs of malnutrition.
Seek urgent medical advice if:
- food or fluids are being kept down very poorly
- there are signs of dehydration
- weight loss is rapid or severe
- pain, vomiting, swallowing difficulty or other worrying symptoms are developing
Common questions
Should I force myself to eat full meals?
Usually not. If full meals are consistently overwhelming, smaller and more frequent intake is often more successful.
Are liquid calories “cheating”?
No. For some people, nourishing drinks are one of the most practical ways to protect weight and strength.
What if I only manage a few foods?
That is still worth discussing. A restricted diet may be understandable, but it can increase nutritional risk over time.
What if dairy feels unpleasant?
Individual experience matters. If a food clearly feels uncomfortable, it may help to try alternatives or use smaller amounts in different forms. But many people do not need to exclude dairy automatically.
Could reflux be making my cough worse?
Yes, it can in some people. Reflux can irritate the upper airway and may contribute to cough or discomfort around meals.
When to seek medical advice
Ask for medical advice if you are losing weight, struggling to eat most days, developing a very restricted diet, or think nausea, reflux or medication side effects are affecting your intake. Ask urgently if you are becoming dehydrated, vomiting repeatedly, or your intake has become extremely poor.
Author and review information
Prepared for: aspergillosis.org
Purpose: general educational information for patients and non-specialists
Review note: Because medicine instructions can change between formulations and brands, patients should always check the current advice supplied with their own prescription and confirm uncertainties with a pharmacist or clinical team.
References and further reading
- Carter C, Muldoon EG, Kosmidis C. Chronic pulmonary aspergillosis - a guide for the general physician. 2024.
PubMed - Tashiro M, Takazono T, Izumikawa K. Chronic pulmonary aspergillosis: comprehensive insights into epidemiology, diagnosis, treatment, and unresolved challenges. 2024.
Free full text - Roboubi A, et al. Allergic bronchopulmonary aspergillosis. 2023.
PubMed - Sunman B, et al. Current approach in the diagnosis and management of allergic bronchopulmonary aspergillosis in children with cystic fibrosis. 2020.
Free full text - Madhavan V, et al. Malnutrition in allergic bronchopulmonary aspergillosis complicating asthma. 2023.
Free full text - British Dietetic Association. Spotting and treating malnutrition.
BDA resource - BAPEN. Food first / food enrichment.
BAPEN resource - BAPEN / Malnutrition Pathway. Managing malnutrition in COPD.
PDF - NICE. Managing malnutrition in COPD, The Malnutrition Pathway.
NICE shared learning resource - NHS. Heartburn and acid reflux.
NHS advice - Cambridge University Hospitals NHS Foundation Trust. Dietary and lifestyle advice for adults with gastro-oesophageal reflux disease (GORD).
CUH advice - NICE BNF. Itraconazole.
BNF drug monograph - Manchester University NHS Foundation Trust, National Aspergillosis Centre. Patient Information: Itraconazole.
PDF - Manchester University NHS Foundation Trust, National Aspergillosis Centre. Patient Information: Voriconazole.
PDF - Oxford University Hospitals NHS Foundation Trust. Advice about antifungals.
PDF - Balfour-Lynn IM. Milk, mucus and myths. Archives of Disease in Childhood. 2019.
Article - Pinnock CB, Graham NM, Mylvaganam A. Relationship between milk intake and mucus production in adult volunteers challenged with rhinovirus-2. 1990.
PubMed - ASCIA. Milk, mucus and cough.
Patient resource
Cystic Fibrosis, CFTR Gene Variants, and Aspergillosis
Last reviewed: 8 April 2026
Some people with aspergillosis are told they have cystic fibrosis (CF), or that they carry a CFTR gene variant. This can be unexpected and may raise concerns about whether this explains their symptoms or diagnosis.
This article explains how cystic fibrosis and CFTR gene variants relate to Aspergillus-related lung disease, what current research shows, and—importantly—what conclusions should not be drawn.
Contents
- Key points
- Important reassurance
- What is cystic fibrosis?
- What is a CFTR gene variant?
- How CFTR affects the lungs
- How Aspergillus behaves in the lungs
- ABPA and cystic fibrosis
- CPA and cystic fibrosis
- Modern CF treatments and Aspergillus
- Does a CFTR variant explain symptoms?
- What should patients take from this?
- When to seek medical advice
- Conclusion
- References
Key points
- Most people with aspergillosis do not have cystic fibrosis.
- Most people with cystic fibrosis do not develop ABPA or CPA.
- ABPA is linked to mucus and immune responses, not just infection.
- CFTR variants may contribute to risk in some people, but are usually only one factor.
- CPA is mainly driven by structural lung damage, not CFTR genetics.
Important reassurance
Most people with aspergillosis do not have cystic fibrosis, and most people with cystic fibrosis do not develop Aspergillus-related disease.
Although these conditions can overlap, they are usually separate. Genetic findings such as CFTR variants should be interpreted carefully and in context.
What is cystic fibrosis?
Cystic fibrosis is a genetic condition caused by changes in the CFTR gene. This gene regulates salt and water movement across cells.
When CFTR function is reduced:
- mucus becomes thick and sticky
- airways are harder to clear
- microorganisms persist more easily
This creates an environment where bacteria and fungi can accumulate over time.
What is a CFTR gene variant?
CFTR variants range from severe mutations (causing cystic fibrosis) to mild or uncertain variants.
Carriers (with one variant):
- are common in the general population
- usually have no symptoms
- may have subtle effects in some cases
These subtle effects may include reduced mucus clearance or increased susceptibility to airway inflammation.
How CFTR affects the lungs
CFTR dysfunction affects the lungs in several key ways:
- Mucus dehydration: mucus becomes thick and difficult to clear
- Impaired clearance: particles and microbes remain in the airways
- Chronic inflammation: immune responses become exaggerated
This combination creates a “retention environment” where inhaled organisms—including Aspergillus—may persist.
How Aspergillus behaves in the lungs
Aspergillus is inhaled by everyone, but its effects vary depending on the lung environment.
- Healthy lungs: spores are cleared
- Impaired clearance: spores may persist
- Sensitive immune system: allergic reactions may develop
- Damaged lungs: chronic infection may develop
This explains why Aspergillus-related disease is diverse and depends heavily on underlying lung conditions.
ABPA and cystic fibrosis
ABPA is an allergic immune reaction to Aspergillus.
It is recognised in cystic fibrosis because:
- mucus retention increases exposure to Aspergillus
- immune responses can be exaggerated
However:
- Many CF patients never develop ABPA
- Most ABPA patients do not have CF
Some studies suggest CFTR variants may increase susceptibility, but this is not consistent across all research.
Key message: ABPA and CF can overlap, but one does not imply the other.
CPA and cystic fibrosis
CPA is a chronic fungal infection that develops in structurally damaged lungs.
The most important risk factor is:
pre-existing lung damage
This includes:
- bronchiectasis
- previous tuberculosis
- COPD
Cystic fibrosis can lead to bronchiectasis, and therefore indirectly increase CPA risk.
However:
- CPA is rarely driven directly by CFTR genetics
- most CPA patients do not have CF
Key message: CPA is primarily a disease of lung structure, not genetics.
Modern CF treatments and Aspergillus
CFTR modulators (such as elexacaftor/tezacaftor/ivacaftor) have transformed CF care.
They:
- improve CFTR function
- thin mucus
- improve clearance
Studies suggest:
- reduced Aspergillus detection in some patients
- fewer ABPA exacerbations in some cases
However:
- ABPA still occurs
- existing lung damage remains
- immune responses are not fully corrected
Overall: these therapies improve risk but do not eliminate Aspergillus-related disease.
Does a CFTR variant explain symptoms?
No single factor explains complex lung disease.
Symptoms may result from:
- underlying lung disease
- infection
- inflammation
- environmental exposure
A CFTR variant may contribute, but is rarely the sole cause.
What should patients take from this?
- CF and CFTR variants can sometimes contribute
- ABPA has the strongest connection
- CPA is mainly driven by lung damage
- Most patients with aspergillosis do not have CF
When to seek medical advice
Seek advice if symptoms worsen, change, or include coughing up blood, fever, or chest pain.
Conclusion
Cystic fibrosis and CFTR gene variants can play a role in some patients with Aspergillus-related lung disease, particularly where mucus clearance is affected. However, they should not be overemphasised. In most cases, they are just one part of a broader clinical picture involving lung structure, immune response, and environmental exposure.
References
- Miller PW et al. (1996)
- Marchand E et al. (2001)
- Eaton TE et al. (2002)
- Agarwal R et al. (2012)
- Chaudhary N et al. (2012)
- Warris A et al. (2019)
- Gamaletsou MN et al. (2018)
- Kosmidis C & Denning DW (2015)
- Moldoveanu B et al. (2021)
- Malik HS et al. (2025)
- Zeng C et al. (2025)
- Bendixen MP et al. (2025)
This article is for general information and does not replace advice from your clinical team.
Voriconazole interactions: what patients need to know
Key points
- Voriconazole interacts with many medicines.
- It affects several liver enzyme pathways, including CYP3A4, CYP2C19, and CYP2C9.
- Its behaviour can vary more from one person to another than some other azoles.
- Some medicines can make voriconazole stronger, while others can make it less effective.
- Visual side effects and sensitivity to sunlight are well recognised with voriconazole.
What is voriconazole?
Voriconazole is an azole antifungal often used in serious fungal infections, including aspergillosis. It can be very effective, but it also has a relatively complex interaction profile.
Why voriconazole interacts with so many medicines
Voriconazole affects several liver enzyme systems, including CYP3A4, CYP2C19, and CYP2C9. It can increase the levels of some medicines, while some other medicines can lower voriconazole levels and reduce its effectiveness.
Because voriconazole metabolism varies between patients, the same combination can affect people differently.
The interaction groups most likely to matter
Steroids
Voriconazole can increase exposure to some steroids, including inhaled steroids, which may increase the risk of steroid side effects.
Medicines that reduce voriconazole levels
Some medicines, including certain anti-seizure medicines and rifampicin-type antibiotics, can reduce voriconazole levels so much that the antifungal may not work properly.
Blood thinners
Some blood thinners may become stronger when taken with voriconazole, increasing bleeding risk.
Heart rhythm medicines
Voriconazole can contribute to QT prolongation, so combinations with other medicines that affect heart rhythm may be particularly important.
Statins
Some statins can become stronger when taken with voriconazole, increasing the risk of muscle side effects.
Immunosuppressants
Medicines such as tacrolimus and ciclosporin can rise significantly with voriconazole and often require specialist monitoring and dose adjustment.
Sedatives and some mental health medicines
Some sedatives and psychiatric medicines can become stronger when combined with voriconazole, increasing the risk of drowsiness, confusion, or other side effects.
Voriconazole-specific issues patients should know
Visual changes
Temporary visual disturbances are well recognised with voriconazole. Patients may notice blurred vision, brighter vision, or changes in colour perception.
Photosensitivity
Voriconazole can increase sensitivity to sunlight. Patients should use sensible sun protection and report new skin changes, especially during long-term treatment.
Variable drug levels
Voriconazole levels can vary between patients, which is one reason some teams use therapeutic drug monitoring in selected situations.
What patients should do in practice
- Tell your clinical team and pharmacist that you are taking voriconazole.
- Check before starting new medicines, including over-the-counter or herbal products.
- Report visual changes, significant sensitivity to sunlight, or a change in symptoms after a medicine change.
- Do not change treatment without advice.
When to seek medical advice
Seek medical advice urgently for severe bleeding, fainting, severe palpitations, marked confusion, or rapid worsening after a medicine change.
Important
This page is educational and does not list every interaction. For a full check, use the BNF interaction checker or speak to a pharmacist or clinician.











